Table 2. The outcome of endovascular treatment for patients with micro-AVMs in the literature.
| Authors | No. of micro-AVMs | Mean age (y/o) | No. of Endo treatment | CO rate By Endo treatment |
Embolic agent | Endo complication | M&M related to Endo procedures | |
|---|---|---|---|---|---|---|---|---|
| As first line | As salvage line (postsurgery) | |||||||
| Willinsky et al. 199214) | 5 | 38.2 | 3 | 0 | 0% (0/3) | All NBCA (34%–40%) | None | None |
| Stiver et al. 20008) | 12 | 35.7 | 2 | 0 | 0% (0/2) | All NBCA | None | None |
| Cellerini et al. 20024) | 10 | 48.8 | 6 | 1 | 71.4% (5/7) | All NBCA | None | None |
| Perrini et al. 20047) | 14 | 44.6 | 8 | 1 | 77.8% (7/9) | All NBCA | 2 (SAH, IVH) → 22% | 1 hemianopsia (11%) |
| Andreou et al. 20082) | 26 | 29.7 | 26 | 0 | 76.9% (20/26) | 25 NBCA (20%–25%) 1 ONYX |
1 perforation 1 ICH (postsurgery) 1 glued catheter → 12% |
1 transient hemiparesis (3.8%) |
| Alén et al. 20133) | 28 | 37.1 | 2 | 0 | 100% (2/2) | All NBCA | None | None |
| De Andrade et al. 20205) | 3 | 40.6 | 3 | 0 | 100% (3/3) | All SQUID18 (EVOH-based agent) | None | None |
| Ferracci et al. 20216) | 20 | 47.3 | 10 | 1 | 81.8% (9/11) | 9 NBCA 2 ONYX | 18.2% | None |
micro-AVMs: micro-arteriovenous malformations; CO: complete occlusion; Endo: endovascular; ICH: intracerebral hemorrhage; IVH: intraventricular hemorrhage; M&M: morbidity and mortality; NBCA: n-butyl-2-cyanoacrylate; SAH: subarachnoid hemorrhage